Literature DB >> 23089758

In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.

Chunfu Wang1, Lourdes Valera, Lingling Jia, Melissa J Kirk, Min Gao, Robert A Fridell.   

Abstract

The NS5A replication complex inhibitor daclatasvir (DCV; BMS-790052) inhibits hybrid replicons containing hepatitis C virus (HCV) genotype 3a (HCV3a) NS5A genes with 50% effective concentrations (EC(50)s) ranging from 120 to 870 pM. Selection studies with a hybrid HCV3a replicon identified NS5A residues 31 and 93 as sites for DCV-selected resistance. Our results support the potential use of DCV as a component in combination therapies for HCV3a chronic infection.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23089758      PMCID： PMC3535966          DOI： 10.1128/AAC.01874-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

Authors:  Stanislas Pol; Reem H Ghalib; Vinod K Rustgi; Claudia Martorell; Greg T Everson; Harvey A Tatum; Christophe Hézode; Joseph K Lim; Jean-Pierre Bronowicki; Gary A Abrams; Norbert Bräu; David W Morris; Paul J Thuluvath; Robert W Reindollar; Philip D Yin; Ulysses Diva; Robert Hindes; Fiona McPhee; Dennis Hernandez; Megan Wind-Rotolo; Eric A Hughes; Steven Schnittman
Journal:  Lancet Infect Dis       Date:  2012-06-18       Impact factor: 25.071

2.  Preliminary study of two antiviral agents for hepatitis C genotype 1.

Authors:  Anna S Lok; David F Gardiner; Eric Lawitz; Claudia Martorell; Gregory T Everson; Reem Ghalib; Robert Reindollar; Vinod Rustgi; Fiona McPhee; Megan Wind-Rotolo; Anna Persson; Kurt Zhu; Dessislava I Dimitrova; Timothy Eley; Tong Guo; Dennis M Grasela; Claudio Pasquinelli
Journal:  N Engl J Med       Date:  2012-01-19       Impact factor: 91.245

3.  Entire nucleotide sequence and characterization of a hepatitis C virus of genotype V/3a.

Authors:  M Sakamoto; Y Akahane; F Tsuda; T Tanaka; D G Woodfield; H Okamoto
Journal:  J Gen Virol       Date:  1994-07       Impact factor: 3.891

4.  Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

Authors:  Robert A Fridell; Chunfu Wang; Jin-Hua Sun; Donald R O'Boyle; Peter Nower; Lourdes Valera; Dike Qiu; Susan Roberts; Xin Huang; Bernadette Kienzle; Marc Bifano; Richard E Nettles; Min Gao
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

5.  Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.

Authors:  Robert A Fridell; Dike Qiu; Lourdes Valera; Chunfu Wang; Ronald E Rose; Min Gao
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

6.  Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.

Authors:  Chunfu Wang; Haichang Huang; Lourdes Valera; Jin-Hua Sun; Donald R O'Boyle; Peter T Nower; Lingling Jia; Dike Qiu; Xin Huang; Aneela Altaf; Min Gao; Robert A Fridell
Journal:  Antimicrob Agents Chemother       Date:  2012-01-03       Impact factor: 5.938

7.  euHCVdb: the European hepatitis C virus database.

Authors:  Christophe Combet; Nicolas Garnier; Céline Charavay; Delphine Grando; Daniel Crisan; Julien Lopez; Alexandre Dehne-Garcia; Christophe Geourjon; Emmanuel Bettler; Chantal Hulo; Philippe Le Mercier; Ralf Bartenschlager; Helmut Diepolder; Darius Moradpour; Jean-Michel Pawlotsky; Charles M Rice; Christian Trépo; François Penin; Gilbert Deléage
Journal:  Nucleic Acids Res       Date:  2006-11-16       Impact factor: 16.971

8.  Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.

Authors:  Paul Targett-Adams; Emily J S Graham; Jenny Middleton; Amy Palmer; Stephen M Shaw; Helen Lavender; Philip Brain; Thien Duc Tran; Lyn H Jones; Florian Wakenhut; Blanda Stammen; David Pryde; Chris Pickford; Mike Westby
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

9.  Identification of hepatitis C virus NS5A inhibitors.

Authors:  Julie A Lemm; Donald O'Boyle; Mengping Liu; Peter T Nower; Richard Colonno; Milind S Deshpande; Lawrence B Snyder; Scott W Martin; Denis R St Laurent; Michael H Serrano-Wu; Jeffrey L Romine; Nicholas A Meanwell; Min Gao
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

10.  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Authors:  Min Gao; Richard E Nettles; Makonen Belema; Lawrence B Snyder; Van N Nguyen; Robert A Fridell; Michael H Serrano-Wu; David R Langley; Jin-Hua Sun; Donald R O'Boyle; Julie A Lemm; Chunfu Wang; Jay O Knipe; Caly Chien; Richard J Colonno; Dennis M Grasela; Nicholas A Meanwell; Lawrence G Hamann
Journal:  Nature       Date:  2010-04-21       Impact factor: 49.962
View more
  21 in total

1.  Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.

Authors:  Mengping Liu; Maria Tuttle; Min Gao; Julie A Lemm
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

Review 2.  Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.

Authors:  Evangelista Sagnelli; Mario Starace; Carmine Minichini; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Nicola Coppola
Journal:  Infection       Date:  2018-08-06       Impact factor: 3.553

Review 3.  Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.

Authors:  Sheng-Shun Yang; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2015-11-05       Impact factor: 6.047

4.  All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Authors:  David R Nelson; James N Cooper; Jacob P Lalezari; Eric Lawitz; Paul J Pockros; Norman Gitlin; Bradley F Freilich; Ziad H Younes; William Harlan; Reem Ghalib; Godson Oguchi; Paul J Thuluvath; Grisell Ortiz-Lasanta; Mordechai Rabinovitz; David Bernstein; Michael Bennett; Trevor Hawkins; Natarajan Ravendhran; Aasim M Sheikh; Peter Varunok; Kris V Kowdley; Delphine Hennicken; Fiona McPhee; Khurram Rana; Eric A Hughes
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425

5.  Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.

Authors:  David B Ascher; Jerome Wielens; Tracy L Nero; Larissa Doughty; Craig J Morton; Michael W Parker
Journal:  Sci Rep       Date:  2014-04-23       Impact factor: 4.379

Review 6.  Daclatasvir: potential role in hepatitis C.

Authors:  Choongho Lee
Journal:  Drug Des Devel Ther       Date:  2013-10-16       Impact factor: 4.162

Review 7.  Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.

Authors:  Moheshwarnath Issur; Matthias Götte
Journal:  Viruses       Date:  2014-11-06       Impact factor: 5.048

Review 8.  Hepatitis C virus NS5A inhibitors and drug resistance mutations.

Authors:  Shingo Nakamoto; Tatsuo Kanda; Shuang Wu; Hiroshi Shirasawa; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

9.  Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.

Authors:  Chunfu Wang; Lingling Jia; Donald R O'Boyle; Jin-Hua Sun; Karen Rigat; Lourdes Valera; Peter Nower; Xin Huang; Bernadette Kienzle; Susan Roberts; Min Gao; Robert A Fridell
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

10.  Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.

Authors:  Prabhav Kalaghatgi; Anna Maria Sikorski; Elena Knops; Daniel Rupp; Saleta Sierra; Eva Heger; Maria Neumann-Fraune; Bastian Beggel; Andreas Walker; Jörg Timm; Hauke Walter; Martin Obermeier; Rolf Kaiser; Ralf Bartenschlager; Thomas Lengauer
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.